Phathom Pharmaceuticals, Inc. (PHAT) vs Shattuck Labs, Inc. (STTK)
A side-by-side comparison of Phathom Pharmaceuticals, Inc. and Shattuck Labs, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PHAT
Phathom Pharmaceuticals, Inc.
$6.56HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
STTK
Shattuck Labs, Inc.
$5.99HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — PHAT vs STTK
growth of $100 · dividends reinvested · last 6yPHAT -83.2% (-25.7%/yr)STTK -66.4% (-16.6%/yr)STTK compounded faster over this window
PHAT STTK
PHAT vs STTK: by the numbers
- •STTK is the larger company ($541M vs $531M market cap).
- •Both run net losses; PHAT's is the smaller (-41.34% vs -5256.80% net margin).
Metrics side by side
Valuation
| Metric | PHAT | STTK |
|---|---|---|
| P/S ratio | 2.21 | 540.91 |
| P/B ratio | N/A | 2.56 |
Profitability
| Metric | PHAT | STTK |
|---|---|---|
| Gross margin | 82.92% | -195.10% |
| Operating margin | -91.36% | -5150.80% |
| Net margin | -41.34% | -5256.80% |
| ROE | N/A | -24.90% |
| ROIC | -23.45% | -26.20% |
Growth (annualized)
| Metric | PHAT | STTK |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -11.25% |
| Total return CAGR (5Y) | -26.93% | -20.11% |
Frequently asked
- How have PHAT and STTK total returns compared?
- Over the past 5 years, PHAT delivered -26.93% and STTK delivered -20.11% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.